Jerjes-Sánchez DC, Comparan NA, Canseco LM, Garza-Ruiz A, García-Sosa A, Reyes-Cerezo E

Language: Spanish
References: 14
Page: 241-248
PDF size: 104.93 Kb.

ABSTRACT

Acute coronary syndromes have a heterogeneous clinical presentation with a broad spectrum for mortality and adverse events. It is mandatory to identify high risk groups for percutaneous coronary intervention and intensive antithrombotic treatment or common risk for standard treatment. In contemporaneous medicine it is important to get adequate risk stratification because the impact of hospitalary costs, antithrombotic and reperfusion treatment on health systems. The current pathophysiology of atherosclerosis is moving from a disease secondary to cholesterol deposit, to an inflammatory disease. In the stratification process, familiar history, chest pain, ST dynamic abnormalities, left ventricular wall motion abnormalities, all have predictive value. The association of indirect endothelial dysfunction, micro or macronecrosis and ventricular dysfunction markers increase this value. In our experience a close relationship among abnormal fibrinolysis, inflammation and anticoagulation proteins with adverse events has been proved in acute coronary syndromes. Other interesting finding –for it accessibility– in acute myocardial infarction under coronary percutaneous intervention is persistent ST elevation, leukocytes and fibrinogen predictive value. In population allelic polymorphisms –455A and –148T and fibrinogen (› 450 mg/dL) were associated with coronary disease. These polymorphisms improve risk stratification of coronary disease to establish a better secondary prevention and treatment.

REFERENCES

1. PANTEGHINI M: Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004; 25: 1187-1196.

2. RENASCA II. A Mexican registry of acute coronary syndromes. GARCIA CA, JERJES-SANCHEZ C, MARTINEZ BP, AZPIRI LJR, AUTREY CA, MARTINEZ SC, ET AL: Arch Cardiol Mex 2005; 75: S18-S30.

3. LIBBY P, THEROUX P: Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488.

4. TANAKA A, SHIMADA K, SANO T, ET AL: Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1594-1599.

5. MAURIELLO A, SANGIORGI G, FRATONI S, ET AL: Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1585-1593.

6. LERMAN A, ZEIHER AM: Endothelial function. Circulation 2005; 111: 363-368.

7. JERJES-SANCHEZ C: Venous and arterial thrombosis. A continuum spectrum of the same disease? Eur Heart J 2005; 26: 1-2.

8. JERJES-SÁNCHEZ C, GARZA-RUÍZ A, GUTIÉRREZ-FAJARDO P, VILLARREAL CG: Nuevas estrategias para la estratificación y tratamiento de los síndromes isquémicos coronarios agudos. Una propuesta. Arch Inst Cardiol Mex 1999; 69: 163-175.

9. JERJES-SANCHEZ, COMPARAN A, IBARRA-FLORES M, DECANINI-ARCAUTE H, PALACIOS J, ARCHONDO T: Interaction between haemostatic and inflammatory factors for increasing rate of adverse events in patients with acute coronary syndromes. Eur Heart J 2001; 22: 451.

10. COMPARAN A, PALACIOS JM, JERJES-SÁNCHEZ C: Leucocitos y su asociación con eventos cardiovasculares adversos en infarto con elevación del ST llevados a intervención coronaria percutánea. Arch Cardiol Mex 2005; 75 supl 3: S91-S98-

11. YARNELLA JWG, PATTERSON CC, SWEETNAMB PM, LOWEC GDO: Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart Jour 2004; 25: 1049-1056.

12. YANO K, GROVE JS, CHEN R, RODRIGUEZ BL, CURB JD, TRACY RP: Plasma Fibrinogen as a Predictor of Total and Cause-Specific Mortality in Elderly Japanese-American Men. Arterioscler Thromb Vasc Biol 2001; 21: 1065-1070.

13. DOGGEN CJ, BERTINA RM, CATS VM, ROSENDAAL FR. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 2000; 110: 935-938.

14. Tesis de doctorado en ciencias con especialidad en biología molecular e ingeniería genética del MC Luis Miguel Canseco Ávila: determinación molecular de marcadores genéticos en síndromes coronarios agudos y su relación con eventos cardiovasculares adversos. Laboratorio de genética molecular del Departamento de Bioquímica de la Facultad de Medicina de la Universidad Autónoma de Nuevo León. Octubre 2005.